Multiple Sclerosis, Secondary Progressive
Neurology
4
Pipeline Programs
2
Companies
2
Clinical Trials
2
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
2
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 1 programs with unclassified modality
On Market (2)
Approved therapies currently available
U
DIMETHYL FUMARATEApproved
dimethyl fumarate
Unknown Companyoral2020
Competitive Landscape
2 companies ranked by most advanced pipeline stage
AS
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Biogendimethyl fumarate
AB ScienceMasitinib
Clinical Trials (2)
Total enrollment: 58 patients across 2 trials
BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis
Start: May 2015Est. completion: Jan 201658 patients
Phase 3Terminated
Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis
Start: Aug 2011Est. completion: Feb 2020
Phase 3Completed
Related Jobs in Neurology
Director, Distribution & Services
Xenon Pharmaceuticals
Remote
13h ago
Senior Medical Science Liaison (NYC Tri-State)
Xenon Pharmaceuticals
Remote
13h ago
$208K - $234K/yr
Director of Medical Affairs
CoMind
Miami, FL
13h ago
Director of Finance
CoMind
London, UK
13h ago
Electronics Engineering Manager
CoMind
London, UK
13h ago
Director of Information Technology
Zavation Medical Products
13h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs — potential near-term approvals
Small Molecule is the dominant modality (100% of programs)
2 companies competing in this space